Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- INTS
- Price
- 0.22
- Stock movement down
- -0.03 (-10.71%)
- Company name
- Intensity Therapeutics, Inc. Common stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 13.42M
- Ent value
- 8.71M
- Price/Sales
- 559.10
- Price/Book
- 1.86
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -89.71%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INTS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 559.10 |
| Price to Book | 1.86 |
| EV to Sales | 363.10 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 60.06M |
| EPS (TTM) | -0.62 |
| FCF per share (TTM) | -0.50 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 24.00K |
| Gross profit (TTM) | -1.00K |
| Operating income (TTM) | -12.04M |
| Net income (TTM) | -11.74M |
| EPS (TTM) | -0.62 |
| EPS (1y forward) | -0.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -4.17% |
| Operating margin (TTM) | -50145.83% |
| Profit margin (TTM) | -48900.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.07M |
| Net receivables | 0.00 |
| Total current assets | 8.19M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 103.00K |
| Total assets | 9.59M |
| Accounts payable | 1.68M |
| Short/Current long term debt | 118.00K |
| Total current liabilities | 2.28M |
| Total liabilities | 2.36M |
| Shareholder's equity | 7.22M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -9.50M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -9.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -162.50% |
| Return on Assets | -122.44% |
| Return on Invested Capital | -161.81% |
| Cash Return on Invested Capital | -130.98% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.23 |
| Daily high | 0.24 |
| Daily low | 0.22 |
| Daily Volume | 3.43M |
| All-time high | 9.88 |
| 1y analyst estimate | 2.90 |
| Beta | 4.22 |
| EPS (TTM) | -0.62 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| INTS | S&P500 | |
| Current price drop from All-time high | -97.74% | -1.82% |
| Highest price drop | -97.74% | -56.47% |
| Date of highest drop | 17 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -66.45% | -10.84% |
| Avg time to new high | 94 days | 12 days |
| Max time to new high | 545 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
13.42M
Marketcap category
Small-cap
Description
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Employees
5
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page